Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sodium-Glucose Transporter 2 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT03878706
What this trial is testing

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

Who this might be right for
Diabetes Mellitus, Type 2
University of Athens 240
Not applicableStudy completedNCT02297620
What this trial is testing

The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients

Who this might be right for
Type 2 Diabetes
Astellas Pharma Inc 8,687
Post-approval studies (Phase 4)Study completedNCT02649465
What this trial is testing

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Who this might be right for
Non-alcoholic Fatty Liver Disease
Kanazawa University 40
Post-approval studies (Phase 4)Active Not RecruitingNCT05147090
What this trial is testing

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients

Who this might be right for
Chronic Hepatitis bNAFLDCirrhosis+3 more
The University of Hong Kong 106
Post-approval studies (Phase 4)Study completedNCT06094920
What this trial is testing

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Who this might be right for
Diabetes Mellitus Type 2 With ProteinuriaDiabetes Mellitus, Type 2Diabetes Mellitus+10 more
University Medical Center Groningen 12
Large-scale testing (Phase 3)Study completedNCT02597049
What this trial is testing

Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Who this might be right for
Type 2 Diabetes Mellitus
Eli Lilly and Company 424
Post-approval studies (Phase 4)Study completedNCT03178591
What this trial is testing

Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Who this might be right for
Diabetes Mellitus, Type 2Ischemic Heart Disease
Chiang Mai University 43
Testing effectiveness (Phase 2)Study completedNCT07610174
What this trial is testing

Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

Who this might be right for
Heart FailureHeart Valve Prosthesis
Kafrelsheikh University 160
Not applicableStudy completedNCT07269197
What this trial is testing

Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes

Who this might be right for
Non-Alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2
Josip Juraj Strossmayer University of Osijek 67
Not applicableStudy completedNCT04184947
What this trial is testing

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Who this might be right for
Type 2 Diabetes
University of Padova 10,000
Not applicableActive Not RecruitingNCT07204743
What this trial is testing

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Who this might be right for
SGLT 2 InhibitorsPediatric Kidney DiseaseProteinuric Diseases+1 more
Al-Quds University 10
Post-approval studies (Phase 4)Not Yet RecruitingNCT07527390
What this trial is testing

CANagliflozin In DIALysis Patients

Who this might be right for
DialysisChronic Kidney Disease (Stages 4 and 5)
University Medical Center Groningen 10
Testing effectiveness (Phase 2)Looking for participantsNCT07482020
What this trial is testing

SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism

Who this might be right for
Atrial Fibrillation (AF)Hypertension
Huashan Hospital 66
Post-approval studies (Phase 4)Study completedNCT03646292
What this trial is testing

Antidiabetic Drugs for Steatotic Liver Disease

Who this might be right for
MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseType 2 DiabetesDigestive System Disease+11 more
Yonsei University 51
Post-approval studies (Phase 4)Not Yet RecruitingNCT07351864
What this trial is testing

Finerenone Plus SGLT2 Inhibitors in Heart Failure

Who this might be right for
Heart Failure
Mansoura University 60
Post-approval studies (Phase 4)Study completedNCT02798744
What this trial is testing

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

Who this might be right for
Diabetes Mellitus, Type 2
University of Leicester 68
Post-approval studies (Phase 4)Study completedNCT02397421
What this trial is testing

Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes

Who this might be right for
Heart FailureDiabetes
University of Dundee 56
Post-approval studies (Phase 4)UnknownNCT06350487
What this trial is testing

The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Who this might be right for
Heart Failure, Preserved Ejection Fraction
Samsung Medical Center 154
Very early researchLooking for participantsNCT05057806
What this trial is testing

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Who this might be right for
Type2 DiabetesHeart Failure With Preserved Ejection Fraction
The University of Texas Health Science Center at San Antonio 30
Post-approval studies (Phase 4)UnknownNCT03631134
What this trial is testing

Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin

Who this might be right for
Type2 Diabetes
Nanjing First Hospital, Nanjing Medical University 100
Next Page